Pharmaceutical company Hikma now offers its vital products to Middle East and North Africa

Hikma Pharmaceuticals PLC (Hikma) has announced its new licensing agreement with Takeda Pharmaceuticals to expand its distribution and products to the Middle East and North Africa (MENA).

The multinational medicinal group, which has offices in London, is to work with the research and development-driven company Takeda to enhance product offerings and reinforce commitment to provide high-quality medicines to patients.

Mazen Darwazah, the vice chairman and CEO of MENA and Emerging Markets, commented: “Our large sales and marketing teams, with particular expertise in promoting cardiovascular and diabetes treatments, are well positioned to drive access for Takeda’s products.

“We are pleased to be building on our partnership with Takeda to bring important medicines to the MENA region. By working with global partners we are strengthening our product portfolio in growing therapeutic areas and reinforcing our commitment to improving patient access to quality medicines.”

Under the terms of the agreement, Hikima has been granted exclusive rights to manufacture and commercialise three of Takeda’s leading primary care products.

The new agreement will build on a long-term strategic relationship between Hikma and Takeda, leveraging Hikma’s substantial sales and manufacturing presence in MENA and extensive experience of building brands in the region.

A spokesman for Takeda commented: “We put patients at the centre of everything we do. As such, our partnership with Hikma is a testament of our commitment to offer patients world-class cardiovascular and metabolism medicines while keeping focus on our therapeutic areas of oncology and gastroenterology.”